Evidence map›Paper›PMID 30609891›Full record

ArticleACS chemical neuroscience2019

Multitarget 1,4-Dioxane Compounds Combining Favorable D

Fabio Del Bello, Dario Ambrosini, Alessandro Bonifazi, Amy H Newman, Thomas M Keck, Mario Giannella, Gianfabio Giorgioni, Alessandro Piergentili, Loredana Cappellacci, Antonio Cilia and 2 more

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Highly Potent and Selective Dopamine DJournal of medicinal chemistry · 2022
    Article
  3. Article
  4. Identification of a Potent and Selective 5-HTACS chemical neuroscience · 2020
    Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fabio Del BelloScuola di Scienze del Farmaco e dei Prodotti della Salute , Università di Camerino , Via S. Agostino 1 , 62032 Camerino , Italy.
Dario AmbrosiniScuola di Scienze del Farmaco e dei Prodotti della Salute , Università di Camerino , Via S. Agostino 1 , 62032 Camerino , Italy.
Alessandro BonifaziMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch , National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health , 333 Cassell Drive , Baltimore , Maryland 21224 , United States.
Amy H NewmanMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch , National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health , 333 Cassell Drive , Baltimore , Maryland 21224 , United States.ORCID 0000-0001-9065-4072
Thomas M KeckMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch , National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health , 333 Cassell Drive , Baltimore , Maryland 21224 , United States.ORCID 0000-0003-1845-9373
Mario GiannellaScuola di Scienze del Farmaco e dei Prodotti della Salute , Università di Camerino , Via S. Agostino 1 , 62032 Camerino , Italy.
Gianfabio GiorgioniScuola di Scienze del Farmaco e dei Prodotti della Salute , Università di Camerino , Via S. Agostino 1 , 62032 Camerino , Italy.ORCID 0000-0002-9576-6580
Alessandro PiergentiliScuola di Scienze del Farmaco e dei Prodotti della Salute , Università di Camerino , Via S. Agostino 1 , 62032 Camerino , Italy.ORCID 0000-0001-6135-6826
Loredana CappellacciScuola di Scienze del Farmaco e dei Prodotti della Salute , Università di Camerino , Via S. Agostino 1 , 62032 Camerino , Italy.ORCID 0000-0001-8155-7211
Antonio CiliaRecordati S.p.A., Drug Discovery , Via Civitali 1 , 20148 Milano , Italy.
Silvia FranchiniDipartimento di Scienze della Vita , Università degli Studi di Modena e Reggio Emilia , Via Campi 103 , 41125 Modena , Italy.ORCID 0000-0002-6320-9712
Wilma QuagliaScuola di Scienze del Farmaco e dei Prodotti della Salute , Università di Camerino , Via S. Agostino 1 , 62032 Camerino , Italy.ORCID 0000-0002-7708-0200

Funding

Novel Dopamine D3 Receptor Ligands ZIADA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 2009 to 2025
$25.9M
Dopamine D2-like Functionally Selective AgonistsZIADA000609 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 2016 to 2020
$2.8M
NOVEL DOPAMINE D3 RECEPTOR LIGANDSZ01DA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 1999 to 2008
$1.8M
Intramural NIH HHS Z01 DA000424Intramural NIH HHS ZIA DA000424
6 · The paper itself

Abstract

The effect of methoxy and hydroxy substitutions in different positions of the phenoxy moiety of the N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-phenoxyethan-1-amine scaffold on the affinity/activity for D

Indexed as

AnimalsAntipsychotic AgentsDopamine D2 Receptor AntagonistsDrug DiscoveryHumansReceptors, Dopamine D4SchizophreniaSerotonin 5-HT1 Receptor AgonistsSerotonin 5-HT2 Receptor AntagonistsStructure-Activity RelationshipAntipsychotic AgentsDopamine D2 Receptor AntagonistsReceptors, Dopamine D4Serotonin 5-HT1 Receptor AgonistsSerotonin 5-HT2 Receptor Antagonists1,4-dioxane derivativesdopamine receptorsmultitarget agentsParkinson’s diseaseschizophreniaSerotonin receptors

Identifiers

PMID30609891
PMCPMC8378419

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.